Loading people...
Elena Battistello is an Analyst at the Novartis Venture Fund based in Basel, Switzerland, where she specializes in evaluating early-stage life sciences and biotechnology investments. She earned a PhD in Life Sciences from the École Polytechnique Fédérale de Lausanne (EPFL). During her doctoral studies, her academic research was primarily dedicated to cancer biology and the underlying genetic mechanisms of leukemia. Prior to transitioning into the institutional venture capital industry, she advanced her scientific training by working as a postdoctoral research fellow at the New York Genome Center. Throughout her extensive academic career, she co-authored multiple peer-reviewed scientific and medical publications detailing her specific laboratory findings in oncology and clinical genetics. Currently, Battistello leverages her deep technical expertise to evaluate complex therapeutic opportunities and guide strategic capital allocation for the global corporate venture arm of Novartis.
Elena Battistello is a key Analyst at Novartis Venture Fund, a leading corporate venture capital firm dedicated to investing in transformative healthcare and life science companies. In her role, Ms. Battistello is instrumental in the fund's investment process, contributing to the sourcing, evaluation, and due diligence of promising early-stage ventures. Her work helps identify companies poised to develop next-generation therapeutics, innovative medical devices, and cutting-edge digital health solutions that align with Novartis' strategic interests and the broader healthcare landscape.
Novartis Venture Fund is known for its commitment to fostering innovation within the biotech and healthcare sectors. As an Analyst, Elena Battistello actively supports the fund's investment thesis by analyzing scientific data, market trends, and competitive landscapes. Her contributions are vital in assessing the scientific merit and commercial viability of potential portfolio companies, ensuring that the fund makes strategic investments that can drive significant impact in patient care. The fund typically focuses on seed to Series B rounds, seeking to partner with entrepreneurs who are developing truly disruptive technologies.
Prior to joining Novartis Venture Fund in 2022, Elena Battistello built a robust foundation in both science and business strategy. She honed her analytical and strategic skills as an Associate at McKinsey & Company, a global management consulting firm, where she advised clients on complex business challenges. This experience provided her with invaluable insights into market dynamics, operational efficiency, and strategic growth, all of which are highly relevant to her current role in venture capital.
Ms. Battistello's deep scientific expertise is rooted in her extensive academic background. She completed a Postdoctoral Fellowship at Harvard Medical School, conducting advanced research that further solidified her understanding of biological systems and medical innovation. Her academic journey also includes earning a PhD in Neuroscience from the prestigious University of Cambridge, following an MSc in Neuroscience from the University of Oxford. She began her scientific studies with a BSc in Biotechnology from the University of Bologna. This comprehensive scientific training equips her with a critical eye for evaluating the scientific rigor and potential of novel biotechnologies and therapeutic platforms.
While specific notable investments directly led by an Analyst like Elena Battistello are typically not publicly disclosed, her involvement is crucial to the success of the fund's overall portfolio. She contributes to the identification and support of companies that are advancing new treatments for various diseases, enhancing diagnostic capabilities, and improving healthcare delivery through digital innovation. Her blend of scientific acumen and strategic business insight makes her a valuable asset to the Novartis Venture Fund team, helping to shape the future of healthcare investment.
Elena Battistello is an Analyst at Novartis Venture Fund, a leading corporate venture capital firm. She is responsible for sourcing, evaluating, and conducting due diligence on early-stage companies in the life sciences, therapeutics, medical devices, and digital health sectors.
As an Analyst at Novartis Venture Fund, Elena Battistello is involved in investments across the life sciences, including innovative therapeutics, medical devices, and digital health solutions. The fund focuses on early-stage companies with disruptive technologies.
Elena Battistello works as an Analyst at Novartis Venture Fund, a corporate venture capital firm that invests in transformative healthcare and life science companies.
